Palvella Therapeutics
PVLA
93 hedge funds and large institutions have $129M invested in Palvella Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 34 reducing their positions, and 12 closing their positions.
30% more capital invested
Capital invested by funds: $99M → $129M (+$29.8M)
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
1% more funds holding
Funds holding: 92 → 93 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 0.75% → 0.7% (-0.06%)
29% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 34
Top Buyers
Top Sellers
PVLA Hedge Fund Activity: Q2 2019 in Review
93 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2019, worth a combined $129M — up 30% from $99M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PVLA positions and 12 closed out — a net gain of 3 holders — while 24 added to existing stakes and 34 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.42M. The largest seller was Tekla Capital Management, cutting an estimated $2.38M.
- 93 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2019, up from 92 in Q1 2019.
- Funds reported $129M of Palvella Therapeutics stock for Q2 2019, up 30% quarter-over-quarter.
- 15 funds opened new Palvella Therapeutics positions in Q2 2019 and 12 closed out, a net change of +3 holders.
- The largest Palvella Therapeutics buyer in Q2 2019 was Millennium Management, an estimated $2.42M added.
- The largest Palvella Therapeutics seller in Q2 2019 was Tekla Capital Management, an estimated $2.38M sold.
Based on aggregated 13F filings for Q2 2019.